{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T21:13:21Z","timestamp":1783977201842,"version":"3.55.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Medical Science Research Project of Hebei","award":["20242051"],"award-info":[{"award-number":["20242051"]}]},{"name":"Medical Science Research Project of Hebei","award":["20242051"],"award-info":[{"award-number":["20242051"]}]},{"name":"Medical Science Research Project of Hebei","award":["20242051"],"award-info":[{"award-number":["20242051"]}]},{"name":"Medical Science Research Project of Hebei","award":["20242051"],"award-info":[{"award-number":["20242051"]}]},{"name":"Medical Science Research Project of Hebei","award":["20242051"],"award-info":[{"award-number":["20242051"]}]},{"name":"Medical Science Research Project of Hebei","award":["20242051"],"award-info":[{"award-number":["20242051"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-025-04038-z","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T11:26:12Z","timestamp":1751369172000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Association between cumulative uric acid exposure and metabolic dysfunction-associated fatty liver disease"],"prefix":"10.1186","volume":"25","author":[{"given":"Yunpeng","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liying","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangming","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"issue":"1","key":"4038_CR1","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases. Hepatology. 2018;67(1):328\u201357.","journal-title":"Hepatology"},{"issue":"1","key":"4038_CR2","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/med.21515","volume":"39","author":"J Cai","year":"2019","unstructured":"Cai J, Zhang XJ, Li H. Progress and challenges in the prevention and control of nonalcoholic fatty liver disease. Med Res Rev. 2019;39(1):328\u201348.","journal-title":"Med Res Rev"},{"issue":"9","key":"4038_CR3","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","volume":"7","author":"K Riazi","year":"2022","unstructured":"Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(9):851\u201361.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"4038_CR4","first-page":"418","volume":"32","author":"[Guidelines for the prevention","year":"2024","unstructured":"[Guidelines for the prevention. And treatment of metabolic dysfunction-associated (non-alcoholic) fatty liver disease (Version 2024)]. Zhonghua Gan Zang Bing Za Zhi. 2024;32(5):418\u201334.","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"4038_CR5","doi-asserted-by":"crossref","unstructured":"Di Mauro S, Scamporrino A, Filippello A, Di Pino A, Scicali R, Malaguarnera R et al. Clinical and molecular biomarkers for diagnosis and staging of NAFLD. Int J Mol Sci. 2021;22(21).","DOI":"10.3390\/ijms222111905"},{"issue":"4","key":"4038_CR6","doi-asserted-by":"publisher","first-page":"548","DOI":"10.3390\/ijms17040548","volume":"17","author":"R Lombardi","year":"2016","unstructured":"Lombardi R, Pisano G, Fargion S. Role of serum uric acid and ferritin in the development and progression of NAFLD. Int J Mol Sci. 2016;17(4):548.","journal-title":"Int J Mol Sci"},{"key":"4038_CR7","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ejim.2022.04.022","volume":"103","author":"S Copur","year":"2022","unstructured":"Copur S, Demiray A, Kanbay M. Uric acid in metabolic syndrome: does uric acid have a definitive role? Eur J Intern Med. 2022;103:4\u201312.","journal-title":"Eur J Intern Med"},{"issue":"3","key":"4038_CR8","doi-asserted-by":"publisher","first-page":"E104","DOI":"10.1111\/hepr.12734","volume":"47","author":"J Liu","year":"2017","unstructured":"Liu J, Xu C, Ying L, Zang S, Zhuang Z, Lv H, et al. Relationship of serum uric acid level with non-alcoholic fatty liver disease and its inflammation progression in non-obese adults. Hepatol Res. 2017;47(3):E104\u201312.","journal-title":"Hepatol Res"},{"issue":"4","key":"4038_CR9","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.jhep.2015.11.022","volume":"64","author":"X Wan","year":"2016","unstructured":"Wan X, Xu C, Lin Y, Lu C, Li D, Sang J, et al. Uric acid regulates hepatic steatosis and insulin resistance through the NLRP3 inflammasome-dependent mechanism. J Hepatol. 2016;64(4):925\u201332.","journal-title":"J Hepatol"},{"issue":"6","key":"4038_CR10","doi-asserted-by":"publisher","first-page":"E1032","DOI":"10.1152\/ajpendo.00518.2020","volume":"320","author":"D Xie","year":"2021","unstructured":"Xie D, Zhao H, Lu J, He F, Liu W, Yu W, et al. High uric acid induces liver fat accumulation via ROS\/JNK\/AP-1 signaling. Am J Physiol Endocrinol Metab. 2021;320(6):E1032\u201343.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"2","key":"4038_CR11","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1097\/BOR.0b013e32835d951e","volume":"25","author":"C Li","year":"2013","unstructured":"Li C, Hsieh MC, Chang SJ. Metabolic syndrome, diabetes, and hyperuricemia. Curr Opin Rheumatol. 2013;25(2):210\u20136.","journal-title":"Curr Opin Rheumatol"},{"issue":"3","key":"4038_CR12","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1055\/s-0035-1562945","volume":"35","author":"M Vacca","year":"2015","unstructured":"Vacca M, Allison M, Griffin JL, Vidal-Puig A. Fatty acid and glucose sensors in hepatic lipid metabolism: implications in NAFLD. Semin Liver Dis. 2015;35(3):250\u201361.","journal-title":"Semin Liver Dis"},{"issue":"2","key":"4038_CR13","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1007\/s12072-015-9682-5","volume":"10","author":"C Xu","year":"2016","unstructured":"Xu C. Hyperuricemia and nonalcoholic fatty liver disease: from bedside to bench and back. Hepatol Int. 2016;10(2):286\u201393.","journal-title":"Hepatol Int"},{"issue":"4","key":"4038_CR14","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1161\/CIRCOUTCOMES.111.963694","volume":"5","author":"S Wu","year":"2012","unstructured":"Wu S, Huang Z, Yang X, Zhou Y, Wang A, Chen L, et al. Prevalence of ideal cardiovascular health and its relationship with the 4-year cardiovascular events in a Northern Chinese industrial City. Circ Cardiovasc Qual Outcomes. 2012;5(4):487\u201393.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"6","key":"4038_CR15","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1097\/HJH.0000000000002453","volume":"38","author":"T Unger","year":"2020","unstructured":"Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International society of hypertension global hypertension practice guidelines. J Hypertens. 2020;38(6):982\u20131004.","journal-title":"J Hypertens"},{"issue":"6","key":"4038_CR16","doi-asserted-by":"publisher","first-page":"e3158","DOI":"10.1002\/dmrr.3158","volume":"35","author":"W Jia","year":"2019","unstructured":"Jia W, Weng J, Zhu D, Ji L, Lu J, Zhou Z, et al. Standards of medical care for type 2 diabetes in China 2019. Diabetes Metab Res Rev. 2019;35(6):e3158.","journal-title":"Diabetes Metab Res Rev"},{"key":"4038_CR17","doi-asserted-by":"crossref","unstructured":"Levey AS, de Jong PE, Coresh J, El Nahas M, Astor BC, Matsushita K et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int. 2011;80(1):17\u201328.","DOI":"10.1038\/ki.2010.483"},{"issue":"1","key":"4038_CR18","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202\u20139.","journal-title":"J Hepatol"},{"issue":"11","key":"4038_CR19","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1111\/hepr.12656","volume":"46","author":"S Ballestri","year":"2016","unstructured":"Ballestri S, Nascimbeni F, Romagnoli D, Lonardo A. The independent predictors of non-alcoholic steatohepatitis and its individual histological features.: insulin resistance, serum uric acid, metabolic syndrome, Alanine aminotransferase and serum total cholesterol are a clue to pathogenesis and candidate targets for treatment. Hepatol Res. 2016;46(11):1074\u201387.","journal-title":"Hepatol Res"},{"issue":"2","key":"4038_CR20","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1515\/CCLM.2010.037","volume":"48","author":"YJ Lee","year":"2010","unstructured":"Lee YJ, Lee HR, Lee JH, Shin YH, Shim JY. Association between serum uric acid and non-alcoholic fatty liver disease in Korean adults. Clin Chem Lab Med. 2010;48(2):175\u201380.","journal-title":"Clin Chem Lab Med"},{"key":"4038_CR21","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3389\/fendo.2020.00179","volume":"11","author":"F Wei","year":"2020","unstructured":"Wei F, Li J, Chen C, Zhang K, Cao L, Wang X, et al. Higher serum uric acid level predicts Non-alcoholic fatty liver disease: A 4-Year prospective cohort study. Front Endocrinol (Lausanne). 2020;11:179.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"4038_CR22","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jhep.2016.08.023","volume":"66","author":"R Hashida","year":"2017","unstructured":"Hashida R, Kawaguchi T, Bekki M, Omoto M, Matsuse H, Nago T, et al. Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: A systematic review. J Hepatol. 2017;66(1):142\u201352.","journal-title":"J Hepatol"},{"issue":"6","key":"4038_CR23","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1016\/j.jhep.2018.08.011","volume":"69","author":"VW Wong","year":"2018","unstructured":"Wong VW, Wong GL, Chan RS, Shu SS, Cheung BH, Li LS, et al. Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease. J Hepatol. 2018;69(6):1349\u201356.","journal-title":"J Hepatol"},{"issue":"10","key":"4038_CR24","doi-asserted-by":"publisher","first-page":"e2338952","DOI":"10.1001\/jamanetworkopen.2023.38952","volume":"6","author":"JN de Brito","year":"2023","unstructured":"de Brito JN, McDonough DJ, Mathew M, VanWagner LB, Schreiner PJ, Gabriel KP, et al. Young adult physical activity trajectories and midlife nonalcoholic fatty liver disease. JAMA Netw Open. 2023;6(10):e2338952.","journal-title":"JAMA Netw Open"},{"issue":"5","key":"4038_CR25","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.jhep.2023.01.024","volume":"78","author":"E Lee","year":"2023","unstructured":"Lee E, Korf H, Vidal-Puig A. An adipocentric perspective on the development and progression of non-alcoholic fatty liver disease. J Hepatol. 2023;78(5):1048\u201362.","journal-title":"J Hepatol"},{"issue":"7","key":"4038_CR26","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.2337\/dc08-0072","volume":"31","author":"A Chatzinikolaou","year":"2008","unstructured":"Chatzinikolaou A, Fatouros I, Petridou A, Jamurtas A, Avloniti A, Douroudos I, et al. Adipose tissue lipolysis is upregulated in lean and obese men during acute resistance exercise. Diabetes Care. 2008;31(7):1397\u20139.","journal-title":"Diabetes Care"},{"issue":"3","key":"4038_CR27","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1002\/hep.28132","volume":"63","author":"A Berzigotti","year":"2016","unstructured":"Berzigotti A, Saran U, Dufour JF. Physical activity and liver diseases. Hepatology. 2016;63(3):1026\u201340.","journal-title":"Hepatology"},{"issue":"1","key":"4038_CR28","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.metabol.2005.07.013","volume":"55","author":"M Kaya","year":"2006","unstructured":"Kaya M, Moriwaki Y, Ka T, Inokuchi T, Yamamoto A, Takahashi S, et al. Plasma concentrations and urinary excretion of purine bases (uric acid, hypoxanthine, and xanthine) and oxypurinol after rigorous exercise. Metabolism. 2006;55(1):103\u20137.","journal-title":"Metabolism"},{"key":"4038_CR29","doi-asserted-by":"publisher","first-page":"572490","DOI":"10.3389\/fendo.2020.572490","volume":"11","author":"S Della Torre","year":"2020","unstructured":"Della Torre S. Non-alcoholic fatty liver disease as a canonical example of metabolic Inflammatory-Based liver disease showing a Sex-Specific prevalence: relevance of Estrogen signaling. Front Endocrinol (Lausanne). 2020;11:572490.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"4038_CR30","doi-asserted-by":"crossref","unstructured":"Della Torre S. Beyond the X factor: relevance of sex hormones in NAFLD pathophysiology. Cells. 2021;10(9).","DOI":"10.3390\/cells10092502"},{"issue":"2","key":"4038_CR31","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jhep.2020.03.006","volume":"73","author":"Z Liu","year":"2020","unstructured":"Liu Z, Zhang Y, Graham S, Wang X, Cai D, Huang M, et al. Causal relationships between NAFLD, T2D and obesity have implications for disease subphenotyping. J Hepatol. 2020;73(2):263\u201376.","journal-title":"J Hepatol"},{"issue":"5","key":"4038_CR32","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/S2468-1253(19)30039-1","volume":"4","author":"J Li","year":"2019","unstructured":"Li J, Zou B, Yeo YH, Feng Y, Xie X, Lee DH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999\u20132019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2019;4(5):389\u201398.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"4038_CR33","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2017.06.003","volume":"67","author":"JG Fan","year":"2017","unstructured":"Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia. J Hepatol. 2017;67(4):862\u201373.","journal-title":"J Hepatol"},{"issue":"8","key":"4038_CR34","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S2468-1253(20)30077-7","volume":"5","author":"Q Ye","year":"2020","unstructured":"Ye Q, Zou B, Yeo YH, Li J, Huang DQ, Wu Y, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(8):739\u201352.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"4038_CR35","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.jhep.2023.03.040","volume":"79","author":"MH Le","year":"2023","unstructured":"Le MH, Le DM, Baez TC, Wu Y, Ito T, Lee EY, et al. Global incidence of non-alcoholic fatty liver disease: A systematic review and meta-analysis of 63 studies and 1,201,807 persons. J Hepatol. 2023;79(2):287\u201395.","journal-title":"J Hepatol"},{"issue":"3","key":"4038_CR36","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1080\/00325481.2022.2039007","volume":"134","author":"G Aktas","year":"2022","unstructured":"Aktas G, Khalid A, Kurtkulagi O, Duman TT, Bilgin S, Kahveci G, et al. Poorly controlled hypertension is associated with elevated serum uric acid to HDL-cholesterol ratio: a cross-sectional cohort study. Postgrad Med. 2022;134(3):297\u2013302.","journal-title":"Postgrad Med"},{"key":"4038_CR37","unstructured":"Kosekli MA, Aktas G, SERUM URIC ACID TO HDL CHOLESTEROL RATIO, IS ASSOCIATED WITH DIABETIC CONTROL IN NEW ONSET TYPE 2 DIABETIC POPULATION. Acta Clin Croat. 2023;62(2):277\u201382."},{"issue":"5","key":"4038_CR38","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1080\/00325481.2023.2214058","volume":"135","author":"G Aktas","year":"2023","unstructured":"Aktas G, Yilmaz S, Kantarci DB, Duman TT, Bilgin S, Balci SB, et al. Is serum uric acid-to-HDL cholesterol ratio elevation associated with diabetic kidney injury? Postgrad Med. 2023;135(5):519\u201323.","journal-title":"Postgrad Med"},{"issue":"3","key":"4038_CR39","first-page":"145","volume":"125","author":"SB Balci","year":"2024","unstructured":"Balci SB, Atak BM, Duman T, Ozkul FN, Aktas G. A novel marker for prediabetic conditions: uric acid-to-HDL cholesterol ratio. Bratisl Lek Listy. 2024;125(3):145\u20138.","journal-title":"Bratisl Lek Listy"},{"issue":"1","key":"4038_CR40","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1590\/1806-9282.65.1.9","volume":"65","author":"MZ Kocak","year":"2019","unstructured":"Kocak MZ, Aktas G, Erkus E, Sincer I, Atak B, Duman T. Serum uric acid to HDL-cholesterol ratio is a strong predictor of metabolic syndrome in type 2 diabetes mellitus. Rev Assoc Med Bras (1992). 2019;65(1):9\u201315.","journal-title":"Rev Assoc Med Bras (1992)"},{"issue":"4","key":"4038_CR41","first-page":"403","volume":"59","author":"O Kurtkulagi","year":"2021","unstructured":"Kurtkulagi O, Tel BMA, Kahveci G, Bilgin S, Duman TT, Ert\u00fcrk A, et al. Hashimoto\u2019s thyroiditis is associated with elevated serum uric acid to high density lipoprotein-cholesterol ratio. Rom J Intern Med. 2021;59(4):403\u20138.","journal-title":"Rom J Intern Med"},{"issue":"5","key":"4038_CR42","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1080\/13685538.2019.1678126","volume":"23","author":"G Aktas","year":"2020","unstructured":"Aktas G, Kocak MZ, Bilgin S, Atak BM, Duman TT, Kurtkulagi O. Uric acid to HDL cholesterol ratio is a strong predictor of diabetic control in men with type 2 diabetes mellitus. Aging Male. 2020;23(5):1098\u2013102.","journal-title":"Aging Male"},{"key":"4038_CR43","doi-asserted-by":"crossref","unstructured":"Kosekli MA, Kurtkulagii O, Kahveci G, Duman TT, Tel BMA, Bilgin S et al. The association between serum uric acid to high density lipoprotein-cholesterol ratio and non-alcoholic fatty liver disease: the abund study. Rev Assoc Med Bras (1992). 2021;67(4):549\u2013\u200954.","DOI":"10.1590\/1806-9282.20201005"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04038-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-025-04038-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04038-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T11:26:15Z","timestamp":1751369175000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-025-04038-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4038"],"URL":"https:\/\/doi.org\/10.1186\/s12876-025-04038-z","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"9 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committees of the Kailuan General Hospital (No. 200605). Written informed consent was provided by all participants. The study was performed in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Yes.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The author declares no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"497"}}